Sivelestat for Organ Protection After Heart Surgery
Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
Recruiting
N/A
Interventional Study
Aortic Dissection
Systemic Inflammatory Response Syndrome
Cardiovascular Diseases (CVD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 500 (estimated)
- Sponsor
- Nanjing Medical University · Other
Who this trial is looking for
This trial is looking for patients who have a specific type of aortic problem and are planning to have emergency heart surgery. Participants will receive a treatment called sivelestat to see if it helps prevent complications after the surgery.
Are You a Good Fit for This Trial?
You may be able to join if
- I have symptoms of thoracic aortic disease within the last two weeks.
- I have type A acute aortic syndrome confirmed by medical tests.
- I am planning to undergo emergency heart surgery.
- I am between 18 and 90 years old.
- I agree to participate in the study and sign the consent form.
You may not be able to join if
- I am allergic to sivelestat sodium.
- I am pregnant or breastfeeding.
- I have mental health issues or substance dependence.
- I refuse to participate in this study.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acu…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
* Patients with type A acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were…
Contacts